Lu Jialin, Ma Yuqing, Li Qiuxin, Xu Yihuan, Xue Yiquan, Xu Sheng
National Key Lab of Immunity and Inflammation and Institute of Immunology, Naval Medical University/Second Military Medical University, Shanghai, 200433, China.
Department of Gastroenterology, Changhai Hospital, Naval Medical University, Shanghai, 200433, China.
Biomark Res. 2024 Aug 23;12(1):86. doi: 10.1186/s40364-024-00637-2.
With the advent of adoptive cellular therapy, chimeric antigen receptor (CAR)-T cell therapy has gained widespread application in cancer treatment and has demonstrated significant efficacy against certain hematologic malignancies. However, due to the limitations of CAR-T cell therapy in treating solid tumors, other immune cells are being modified with CAR to address this issue. Macrophages have emerged as a promising option, owing to their extensive immune functions, which include antigen presentation, powerful tumor phagocytosis, and particularly active trafficking to the tumor microenvironment. Leveraging their unique advantages, CAR-macrophages (CAR-M) are expected to enhance the effectiveness of solid tumor treatments as a novel form of immunotherapy, potentially overcoming major challenges associated with CAR-T/NK therapy. This review outlines the primary mechanism underlying CAR-M and recent progressions in CAR-M therapy, while also discussing their further applications.
随着过继性细胞疗法的出现，嵌合抗原受体（CAR）-T细胞疗法在癌症治疗中得到了广泛应用，并已证明对某些血液系统恶性肿瘤具有显著疗效。然而，由于CAR-T细胞疗法在治疗实体瘤方面存在局限性，其他免疫细胞正被用CAR进行改造以解决这一问题。巨噬细胞因其广泛的免疫功能而成为一个有前景的选择，这些功能包括抗原呈递、强大的肿瘤吞噬作用，以及特别活跃地向肿瘤微环境迁移。利用其独特优势，CAR巨噬细胞（CAR-M）有望作为一种新型免疫疗法提高实体瘤治疗的有效性，有可能克服与CAR-T/NK疗法相关的主要挑战。本综述概述了CAR-M的主要作用机制以及CAR-M疗法的最新进展，同时也讨论了它们的进一步应用。
